Nakayama RT, Pulice JL, Valencia AM, et al. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat Genet. 2017;49(11):1613-1623. doi:10.1038/ng.3958.

Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806. doi:10.1126/science.aan5951.

Lee RS, Stewart C, Carter SL, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012;122(8):2983-8. doi:10.1172/JCI64400.

Wilson BG, Helming KC, Wang X, et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol. 2014;34(6):1136-44. doi:10.1128/MCB.01372-13.

Galonska C, Smith ZD, Meissner A. In Vivo and in vitro dynamics of undifferentiated embryonic cell transcription factor 1. Stem Cell Reports. 2014;2(3):245-52. doi:10.1016/j.stemcr.2014.01.007.

Theurillat J-PP, Udeshi ND, Errington WJ, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346(6205):85-9. doi:10.1126/science.1250255.

Swamidass J, Calhoun BT, Bittker JA, Bodycombe NE, Clemons PA. Utility-aware screening with clique-oriented prioritization. J Chem Inf Model. 2012;52(1):29-37. doi:10.1021/ci2003285.

Kim KH, Kim W, Howard TP, et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 2015;21(12):1491-6. doi:10.1038/nm.3968.

Flavahan WA, Drier Y, Liau BB, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529(7584):110-4. doi:10.1038/nature16490.

Surface LE, Fields PA, Subramanian V, et al. H2A.Z.1 Monoubiquitylation Antagonizes BRD2 to Maintain Poised Chromatin in ESCs. Cell Rep. 2016;14(5):1142-55. doi:10.1016/j.celrep.2015.12.100.